METBEIGE biomarker study

Biomarker study auxiliary to "a multi-center phase I/II study of cabozantinib and panitumumab combination therapy or cabozantinib monotherapy in patients with MET amplified metastatic colorectal cancer (short title: METBEIGE study)"

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224637

Enrollment

Registered

2019-04-12

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

investigational material(s) Generic name etc : Cabozantinib Malate INN of investigational material : Cabozantinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for I

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study

Exclusion criteria

Exclusion criteria: Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study

Design outcomes

Primary

Measure	Time frame
pharmacogenomics Analyses will be performed of the following parameters using formalin-fixed and paraffin-embedded (FFPE) specimens and freshly frozen specimens prepared from tumor tissue collected for the METBEIGE study (before protocol treatment, before the start of the second cycle, and after discontinuation of protocol treatment) and blood specimens collected at the same time. The results obtained from the analyses will be integrated with clinical data obtained in the METBEIGE study to identify biomarkers of the effectiveness of the protocol treatment. 1)Analysis of cancer-related genetic abnormalities 2)Protein expression analysis 3)RNA expression analysis 4)Analysis of cancer cell lines and organoids 5)Patient-derived Xenografts (PDX) analysis	—

Measure

Time frame

pharmacogenomics Analyses will be performed of the following parameters using formalin-fixed and paraffin-embedded (FFPE) specimens and freshly frozen specimens prepared from tumor tissue collected for the METBEIGE study (before protocol treatment, before the start of the second cycle, and after discontinuation of protocol treatment) and blood specimens collected at the same time. The results obtained from the analyses will be integrated with clinical data obtained in the METBEIGE study to identify biomarkers of the effectiveness of the protocol treatment. 1)Analysis of cancer-related genetic abnormalities 2)Protein expression analysis 3)RNA expression analysis 4)Analysis of cancer cell lines and organoids 5)Patient-derived Xenografts (PDX) analysis

—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026